

**AMENDMENTS TO THE CLAIMS:**

Amend the claims as follows:

1. (Currently Amended) A method for inhibiting KDR/Flk-1 signal transduction in endothelial cells, which comprises contacting the cells with a monoclonal antibody or an antibody fragment thereof, wherein said antibody and antibody fragment thereof which specifically recognize[[s]] 1175-tyrosine phosphorylated KDR/Flk-1.

2. (Currently Amended) A method for inhibiting cell growth of endothelial cells, which comprises contacting the cells with a monoclonal antibody or an antibody fragment thereof, wherein said antibody and antibody fragment thereof which specifically recognize[[s]] 1175-tyrosine phosphorylated KDR/Flk-1 ~~or an antibody fragment thereof~~.

Claims 3-9 (Canceled).

10. (Previously Presented) The method according to any one of claims 1 to 2, wherein the monoclonal antibody inhibits binding of phospholipase C- $\gamma$  (PLC- $\gamma$ ) to 1175-tyrosine phosphorylated KDR/Flk-1.

Claims 11-42. (Cancelled)

43. (Previously Presented) The method according to any one of claims 1 to 2, wherein the monoclonal antibody is a humanized anti-1175-tyrosine phosphorylated

KDR/Flk-1 antibody which binds to an epitope which is recognized by an antibody produced by a hybridoma KM3035 (FERM BP-7729).

44. (Currently Amended) The ~~[[m80ethod]]~~method according to claim 43, wherein the humanized anti-1175-tyrosine phosphorylated KDR/Flk-1 antibody is a human chimeric antibody or a human complementarity-determining region (CDR)-grafted antibody.